Optimal Surgical Approach for Early-Stage Breast Cancer in Chinese Patients Aged ≤ 40 Years: a Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 974
- 主要终点
- Breast cancer-specific survival (BCSS)
研究概览
简要总结
The optimal surgical treatment option (BCS+RT versus MAST) for young patients with early-stage breast cancer remains debated. The present study aims to explore trends in surgical management and compare survival outcomes between BCS+RT and MAST in young patients with early-stage breast cancer, ultimately providing optimal treatment strategies for Asian populations.
详细描述
This study is a unique addition to the current research on young women with early-stage breast cancer, aiming to compare the survival outcomes between BCS+RT and MAST, providing valuable insights into their effectiveness for this group of patients. This study enrolled patients at West China Hospital, Sichuan University. Kaplan-Meier analyses with the log-rank test were applied to compare the locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), breast cancer-specific survival (BCSS), and overall survival (OS). Cox multivariate hazard regression was employed to assess hazard ratios (HRs) between the two groups for survival outcomes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18-40 years.
- •Pathological diagnosis of invasive breast cancer.
- •Undergoing Breast-Conserving Surgery (BCS) with Radiotherapy (RT) or Mastectomy (MAST).
- •Availability of detailed clinical information, including:
- •Tumor (T) stage. Node (N) stage. Clinical stage. Hormone receptor status. Endocrine therapy details. Targeted therapy details.
排除标准
- •Male patients.
- •Patients with distant metastatic disease.
- •Patients with bilateral breast cancer.
- •Patients not undergoing surgery.
- •Follow-up time of less than 1 month.
结局指标
主要结局
Breast cancer-specific survival (BCSS)
时间窗: Jan 1, 2008 to 31 Dec, 2019
LRFS (Locoregional Recurrence-Free Survival)
时间窗: Jan 1, 2008 to 31 Dec, 2019
DMFS (Distant Metastasis-Free Survival)
时间窗: Jan 1, 2008 to 31 Dec, 2019
OS (Overall Survival)
时间窗: Jan 1, 2008 to 31 Dec, 2019
次要结局
未报告次要终点
研究者
Lei Liu
Principal Investigator
West China Hospital